Evidence indicates that the growth hormone (GH)-IGF-1 axis plays a significant role in cancer incidence and progression, supported by epidemiological studies linking elevated plasma IGF-1 levels to increased cancer risk and the observed absence of cancers in individuals with GH/IGF-1 deficiency [165]. Here, GH1 is linked to hyperinsulinemic hypoglycemia, familial, 4.